title: Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
abstract: The treatment of breast cancer has progressed substantially over the past 15 years. Data from randomized adjuvant trials have shown that the risk of disease recurrence and death is significantly reduced when adjuvant chemotherapy and/or hormonal therapy is added to treatment. As new strategies are incorporated, one of the continued controversies in patient management is whether adjuvant anthracyclines should be the preferred treatment for all patients. Data from randomized and translational clinical trials have become available and are helping to elucidate the proper role of anthracyclines, as well as their acute and long-term toxicities. In most situations, an anthracycline is currently preferred, but other single and combination chemotherapies are currently under evaluation and appear promising for use in the adjuvant setting. Continued breast cancer research using molecular markers (such as topoisomerase II-alpha and gene clusters) as predictors of treatment response, could help individualize decisions regarding whether to incorporate anthracyclines into adjuvant therapy regimens.
authors.affiliation: Department of Internal Medicine, Mayo Graduate School of Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA.
authors.forename: Dina K
authors.initials: DK
authors.lastname: Tack
authors.forename: Frances M
authors.initials: FM
authors.lastname: Palmieri
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage
chemical_list: D018943:Anthracyclines; D003841:Deoxycytidine; D015251:Epirubicin; D000069287:Capecitabine; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil; D008727:Methotrexate